Faculty Information - Junichi Kurebayashi

Present specialized field

Journal

Presentation

Belonging society

（Last updated : 2024-09-20 11:40:38）

Junichi Kurebayashi
Department Kawasaki University of Medical Welfare ,

Position Professor with Special Assignment

■ Present specialized field

General surgery and pediatric surgery, Molecular biology, Cell biology

■ Journal

1.	2024/03/19	Epithelial-mesenchymal transition in tumor cells is correlated with prognosis, and activated intra-tumor immunity is correlated with chemo-sensitivity in breast cancer patients with a non-pathological complete response to neoadjuvant chemotherapy.
2.	2022/11/21	Role of the expression of collagen prolyl-4-hydroxylase α subunits 1 and 2 in the development and prognosis of breast cancer
3.	2021/05	A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
4.	2021/04	A Case of Takotsubo syndrome after Surgery for Papillary Thyroid Cancer.
5.	2021/04	A giant axillary mass treated as breast cancer metastasis.
6.	2021/01	Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
7.	2020/10/01	Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
8.	2020/09/11	Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging.
9.	2020/08	Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy.
10.	2020/05	Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
11.	2020/05	Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Display 5 items
Display all(11)

■ Presentation

1.	2019/03/21	Effects of long-term hypoxia and/or endocrine manipulation on endocrine sensitivity in MCF-7 cells. （Poster notice，General）
2.	2017/04/03	Heat shock protein 90 inhibitors suppress PDGFRA reactivation and other receptor tyrosine kinase activation important in drug resistant gastrointestinal stromal tumors. （Poster notice，General）
3.	2016/11/19	Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 and antiestrogens in estrogen receptor-positive breast cancer cells （Speech，Special/Invited Lecture）
4.	2015/12/11	Hormone dynamics, pharmacokinetics, safety and efficacy of leuprorelin acetate 6-month depot formulation and tamoxifen adjuvant endocrine therapy combination in premenopausal patients with hormone-positive breast cancer. （Poster notice，General）
5.	2015/11/15	Antitumor and anti-cancer stem cell activity of eribulin mesylate in breast cancer: preclinical evidence and clinical implication. （Speech，Special/Invited Lecture）
6.	2015/03/19	QOL score changes in breast cancer patients: 2-year vs. 3-or-more-year administration of leuprorelin. （Poster notice，General）
7.	2015/03/18	Antitumor and anti-cancer stem cell activities of eribulin and antiestrogens in breast cancer cells. （Poster notice，General）
8.	2014/02/15	Biological markers: as guidance for clinical decision in breast cancer treatment and their limits. （Speech，Special/Invited Lecture）
9.	2013/03/14	Effects of antiestrogens on the cell growth and regulation of cancer stem cell population in breast cancer cells. （Poster notice，General）
10.	2013/03/14	Prognostic factors in HER2-positive breast cancer patients treated with adjuvant trastuzumab and chemotherapy. （Poster notice，General）
11.	2012/06/28	Characteristics of breast cancer subtypes advocated by the St. Gallen Consensus Conference. （Speech，General）
12.	2012/03/21	Anti-tumor and anti-cancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. （Poster notice，General）
13.	2011/11/25	Endoscopic Breast Surgery for Benign Breast Tumors. （Speech，General）
14.	2010/11/25	Endscopic Breast Sugery for Benign Breast Tumors. （Speech，General）
15.	2010/11/25	Nipple-Patch After Skin Sparing Mastectomy without preserving the Nipple-Areola-Complex. （Speech，General）
16.	2010/07/24	New tactics of HER2-positive breast cancer treatment after trastuzumab. （Speech，Special/Invited Lecture）
17.	2010/03/24	The cell cycle profile (C2P) test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy （Poster notice）
18.	2010/03/23	A Case of neuroendocrine carcinoma of thyroid (small cell type) （Poster notice，General）
19.	2010/03/23	Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma （Poster notice，General）
20.	2010/03/23	Analysis of patients with primary hyperparathyroidism (PHP) due to hyperplasia （Poster notice，General）
21.	2008/05/15	乳癌内分泌療法における未解決問題(Controversy of endocrine therapy in breast cancer) （Panelist at Symposium/Workshop (Other)）
22.	2008/02/16	Current clinical trials for endocrine therapy in breast cancer. （Speech，Special/Invited Lecture）
23.	2008/02/15	Serum tumor markers in breast cancer. （Speech，Special/Invited Lecture）
24.	2007/12/13	Significance of serum tumor markers in monitoring breast cancer patients. （Speech，Special/Invited Lecture）
25.	2007/10/11	Translating genetics to cancer prevention. （Speech，Panelist at Symposium/Workshop (Other)）
26.	2007/10/11	Which is the better treatment option between up-front and switch treatment? （Speech，Panelist at Symposium/Workshop (Other)）
27.	2007/10/03	Quantitative diagnosisi by using Elastography in breast disease （Poster notice，General）
28.	2007/03/15	The diversity of small tumors around the world: Are there implications for local and systemic therapies?
29.	2006/09/16	Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-α-positive breast cancer cells.
30.	2006/09/16	Combined antitumor effects of the HER1/HER2 dual inhibitor, lapatinib with antiestrogens in breast cancer cells.
31.	2006/09/16	Predictive factors for response to combined therapy with docetaxel and doxifluridine in patients with advanced breast cancer.
32.	2005/04/22	Progress report on the WSBH Project entitled “Comparison of clinicopathological characteristics of breast cancer among different countries and geographic areas”.
33.	2005/03/01	Resistance to endocrine therapy in breast cancer.
34.	2004/05/13	Radio Isotope (RI) and dye combined, video-guided sentinel node group dissection of the breast cancer
35.	2004/01/08	Retrospective analysis of paclitaxel administration as adjuvant therapy for breast cancer patients.
36.	2003/04/03	A case of apocrine DCIS and LCIS in one breast. （Poster notice，General）
Display 5 items
Display all(36)

■ Belonging society

1.	1990～2021/12	American Association for Cancer Research
2.	1994～2021/12	International Society of Surgery
3.	1994～	International Association for Endocrine Surgeons
4.	1996～2021/12	American Society of Clinical Oncology
5.	2006～	International Association for Breast Cancer Research
6.	2008/09～	∟ Governor
Display 5 items
Display all(6)